View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

GSK- A New Dawn – Double Upgrade (BUY, TP £17, 33pgs)

For access to the full note, please contact Naresh Chouhan ( )

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

GSK & Sanofi - Time To Divest Vaccines? (23pgs)

For access to the full note, please contact Naresh Chouhan ( )

Novartis AG: 1 director

A director at Novartis AG sold 2,600 shares at 97.158CHF and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 2,350 shares at 349.044DKK and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Abbvie Inc: 1 director

A director at Abbvie Inc sold 13,295 shares at 198.512USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 July 2025 in which we reassessed the appropriateness of the ratings in the context of the re...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Christian Arnold ... (+2)
  • Christian Arnold
  • Tobias Fahrenholz

ODDO : Swiss Equities Conference Feedback – Difficult Q2 but some H2 2...

ODDO BHF and Commerzbank jointly hosted the Swiss Equities Conference in Interlaken, Switzerland, from 10 to 12 June 2025. The event was attended by 64 companies (out of which 59 are listed, and with BASF one non-Swiss company). Some 125 investors met mostly (85%) C-level management in 440 meetings (one-on-one, one-to-few) and plenary sessions, resulting in some 1,100 interactions. Based on our positive assessments for Q2 & H2 2025 as well as beyond, we would like to highlight Accelleron (poten...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch